Abstract / Summary
ABSTRACT Type 2 diabetes mellitus (T2DM) is a rapidly expanding non-communicable disease pandemic disproportionately affecting low- and middle-income countries (LMICs). Kyrgyzstan, a lower-middle-income country in Central Asia with a population of approximately seven million, faces a growing T2DM burden compounded by rising obesity rates, physical inactivity, nutritional transition, and a healthcare infrastructure undergoing significant post-Soviet reform. Despite the magnitude of this epidemic, no comprehensive English-language review has synthesized current evidence on T2DM epidemiology, risk factors, complications, and management challenges specific to Kyrgyzstan. This comprehensive narrative review aims to synthesize current evidence on the epidemiology, pathophysiology, risk factors, diagnostic criteria, complication burden, and clinical management of T2DM, with explicit emphasis on the Kyrgyz population and the unique challenges of resource-limited Central Asian healthcare settings. A structured literature search was conducted across PubMed/MEDLINE, the WHO Global Health Library, and the International Diabetes Federation (IDF) Atlas database from January 2010 to December 2024. Search terms included "type 2 diabetes" AND "Kyrgyzstan"; "diabetes mellitus" AND "Central Asia"; "T2DM management" AND "resource-limited"; and "diabetic complications" AND "epidemiology." Priority was given to systematic reviews, meta-analyses, national registry data, WHO and IDF reports, and randomized controlled trials. Fifteen high-quality indexed references meeting eligibility criteria were incorporated. T2DM prevalence in Kyrgyzstan is estimated at 8.8–9.4% of the adult population, with national registry data (State Register of Diabetes Mellitus, SRDP) documenting 85,142 registered patients as of January 2024. The most prevalent complications among registered Kyrgyz T2DM patients include diabetic peripheral neuropathy (34.2%), cardiovascular disease (28.6%), and diabetic retinopathy (17.1%). Key modifiable risk factors include obesity, physical inactivity, high-carbohydrate dietary patterns, and hypertension. Metformin and sulfonylureas remain the cornerstone of pharmacological management in Kyrgyzstan due to their availability on the national Essential Medicines List, while newer agents such as SGLT-2 inhibitors and GLP-1 receptor agonists are largely unavailable. A structured five-step management algorithm adapted to the Kyrgyz context is proposed. T2DM represents a major and growing public health challenge in Kyrgyzstan. Substantial gaps between current clinical management capabilities and evidence-based best practice underscore the urgent need for national T2DM prevention programs, expanded diagnostic capacity, affordable access to essential antidiabetic medicines, and structured complication surveillance. Contextually adapted clinical guidelines and investment in primary care capacity are critical for reducing the long-term morbidity and mortality burden of T2DM across Kyrgyzstan and the Central Asian region. Keywords: type 2 diabetes mellitus; Kyrgyzstan; Central Asia; epidemiology; complications; management; insulin resistance; resource-limited settings INTRODUCTION Type 2 diabetes mellitus (T2DM) is one of the most prevalent and consequential non-communicable diseases (NCDs) of the 21st century. According to the International Diabetes Federation (IDF) Diabetes Atlas 10th Edition, an estimated 537 million adults worldwide were living with diabetes in 2021, with T2DM accounting for over 96% of all cases [1]. The global burden is increasingly concentrated in LMICs, where more than three-quarters of people with diabetes reside and where healthcare systems are least equipped to manage the long-term complexity of the disease and its complications [2]. The economic burden — estimated at USD 966 billion globally in direct healthcare costs in 2021 — represents an existential challenge to health financing in resource-constrained nations. Kyrgyzstan presents a particularly instructive case study in the intersection of epidemiological transition, health system constraints, and the rising T2DM burden. A landlocked mountainous country with a population of approximately seven million, Kyrgyzstan is classified by the World Bank as a lower-middle-income country with a per capita gross domestic product of approximately USD 1,400. The country's healthcare system, inherited from the Soviet model and significantly restructured following independence in 1991, continues to struggle with inadequate primary care capacity, limited diagnostic infrastructure in rural areas, inconsistent supply of essential medicines, and a shortage of specialist endocrinologists outside the capital, Bishkek [3]. The epidemiological landscape of T2DM in Kyrgyzstan reflects the convergence of genetic predispositions unique to the Kyrgyz ethnic population, rapid urbanization with associated lifestyle transitions, rising obesity rates, and high prevalence of co-morbid hypertension and dyslipidemia [4]. National registry data from the State Register of Diabetes Mellitus (SRDP) document a 27.6% increase in registered T2DM incidence between 2016 and 2019, highlighting the accelerating pace of the epidemic [5]. The broader global context of NCD prevention that frames this review is aligned with the WHO Global Action Plan for the Prevention and Control of Noncommunicable Diseases [6]. The objectives of this review are: (1) to describe T2DM epidemiology globally and in Kyrgyzstan; (2) to review pathophysiology and diagnostic criteria; (3) to synthesize evidence on risk factors specific to the Kyrgyz population; (4) to characterize the T2DM complication burden; and (5) to present an evidence-based management framework adapted to the resource-limited Kyrgyz context. GLOBAL AND REGIONAL EPIDEMIOLOGY OF T2DM Global Burden The global epidemic of T2DM constitutes one of the most significant public health emergencies of the modern era. The Global Burden of Disease (GBD) Study 2021 estimated that 529 million individuals were living with diabetes globally, with the age-standardized prevalence increasing from approximately 4.6% in 2000 to 9.3–10.5% in 2021, with projections suggesting continued escalation to 12–13% by 2045 driven predominantly by urbanization, aging populations, and the global obesity epidemic [2]. T2DM was responsible for approximately 6.7 million deaths in 2021, representing one death every five seconds. The geographic distribution of the T2DM burden is inequitable: the fastest-growing epidemic is concentrated in South and Southeast Asia, the Middle East, and Central Asia — regions with rapid nutritional transition, genetic predisposition to insulin resistance, and healthcare systems with limited prevention and management capacity [1]. Figure 1 illustrates T2DM prevalence trends from 2000 to 2030 for Kyrgyzstan, the Central Asian regional average, and the global average (Panel A), and a comparison of T2DM prevalence across world regions based on IDF Atlas 2021 data (Panel B). Figure 1 was created by the authors using publicly available datasets from the IDF Atlas [1] and GBD 2021 Study [2]. Figure 1. T2DM Prevalence Trends and Regional Comparisons (Created by Authors). Panel A: Estimated T2DM prevalence trends (2000–2030) for Kyrgyzstan, Central Asia, and the global average. Panel B: Comparative T2DM prevalence (%) by world region. Data sources: IDF Diabetes Atlas, 10th Edition (2021) [1]; GBD 2021 Diabetes Collaborators, Lancet (2023) [2]; Kyrgyz SRDP (2024) [5]. T2DM in Kyrgyzstan: National Registry Data The most authoritative source of T2DM epidemiological data in Kyrgyzstan is the State Register of Diabetes Mellitus (SRDP). Analysis of SRDP data from 2016 to 2023 reveals that the total number of registered diabetic patients reached 85,142 as of January 2024 — equivalent to approximately 1.2% of the total national population [5]. Among registered T2DM patients, females predominate at 59.9%, consistent with higher rates of obesity and physical inactivity documented among Kyrgyz women. The registered T2DM incidence rate increased from 85 per 100,000 population in 2016 to a peak of 108.5 per 100,000 in 2019 — a 27.6% increase — before declining slightly during the COVID-19 pandemic period, likely reflecting reduced healthcare access rather than a true decrease in disease burden [5]. IDF Atlas modeling estimates the true adult T2DM prevalence at 8.8–9.4%, yielding an estimated 400,000–500,000 individuals living with T2DM when undiagnosed cases are included [1]. Regional Comparison: Central Asian Context Kyrgyzstan's T2DM prevalence profile aligns with neighboring Central Asian states. Kazakhstan reports an adult T2DM prevalence of approximately 9.7%, while Uzbekistan and Tajikistan report 8.4% and 7.2%, respectively [1,2]. All Central Asian countries share common epidemiological risk factor profiles — high hypertension rates, rising obesity, traditional diets rich in refined carbohydrates, and historically low structured physical activity. A distinctive feature of Kyrgyz epidemiology is the altitude gradient in T2DM risk: native residents of low-altitude regions carry significantly higher T2DM risk compared to high-altitude populations, as documented by Esenamanova et al. in a study of 3,190 Kyrgyz adults using the FINDRISC screening tool [4]. This altitude-related finding is discussed further in the Risk Factors section in the context of Figure 2. REVIEW METHODOLOGY This narrative review was conducted following a structured, pre-defined search strategy. Electronic databases searched included PubMed/MEDLINE, the Cochrane Library, WHO Global Health Library, and the IDF Diabetes Atlas (10th edition, 2021). The Kyrgyz State Register of Diabetes Mellitus (SRDP) data published through January 2024 were also accessed. Search terms were applied using Boolean operators: "type 2 diabetes mellitus" AND "Kyrgyzstan"; "diabetes m